Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Weight gain with add-on s… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Weight gain with add-on second-generation antipsychotics in bipolar disorder: a naturalistic study

Artikel i vetenskaplig tidskrift
Författare Hemen Najar
Erik Joas
Mathias Kardell
Erik Pålsson
Mikael Landén
Publicerad i Acta Psychiatrica Scandinavica
Volym 135
Nummer/häfte 6
Sidor 606-611
ISSN 0001-690X
Publiceringsår 2017
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 606-611
Språk en
Länkar 10.1111/acps.12737
Ämnesord bipolar disorder, antipsychotic, weight gain, psychotropic-drug prescription, i disorder, insulin-secretion, obesity, status, olanzapine, risperidone, lithium, association, predictors, diagnoses
Ämneskategorier Psykiatri, Endokrinologi och diabetes

Sammanfattning

ObjectiveOur aim was to investigate the prevalence and magnitude of weight gain in-patients with bipolar disorder when treated with a second-generation antipsychotic as an add-on treatment to a mood stabilizer in routine clinical practice. MethodsData were derived from the quality register for bipolar disorder in Sweden (BipolaR). Patients with bipolar disorder who started add-on treatment with a SGA (n=575) were compared at next yearly follow-up with age and sex matched patients who were only treated with a mood stabilizer (n=566). The primary outcome measure was change in body weight and body mass index (BMI). We also assessed the prevalence of clinically significant weight gain defined as 7% gain in body weight. ResultsThe group that received add-on treatment with antipsychotics neither gained more weight nor were at higher risk for a clinically significant weight gain than the reference group. Instead, factors associated with clinically significant weight gain were female sex, young age, low-baseline BMI, and occurrence of manic/hypomanic episodes. ConclusionWe found no evidence of an overall increased risk of weight gain for patients with bipolar disorder after receiving add-on SGA to a mood stabilizer in a routine clinical setting.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?